AACR Conference Coverage

ASCO COVID-19 Data Presented at AACR Virtual Annual Meeting

(ASCO in Action) July 23, 2020 - COVID-19 data collection efforts by the American Society of Clinical Oncology (ASCO) were featured in three separate abstracts during the Association for Cancer Research (AACR) Virtual Meeting: COVID-19 and Cancer this week.

read article

Cancer Is Not Going Away During COVID-19: Physician-in-Chief Lisa DeAngelis Shares Why Patients Need to Get Back to the Clinic

(MSK/In the News) July 24, 2020 - At the 2020 AACR Virtual Meeting: COVID-19 and Cancer the overarching message echoed throughout the meeting was that cancer is not going away during the COVID- 19 pandemic.

read article

Syapse Highlights Real-World Evidence Related to COVID-19 and Cancer at AACR Virtual Meeting

(Syapse) July 22, 2020 - Syapse® today announced results based on real-world data that were highlighted at the AACR Virtual Meeting on COVID-19 and Cancer.

read corporate press release

AACR COVID-19 And Cancer Virtual Meeting: Cancer Researchers Shift Focus To The Pandemic

(AACR/Cancer Research Catalyst) July 23, 2020 - In the global battle against the COVID-19 pandemic, cancer researchers are proving to be formidable forces.

read article

AACR Virtual Meeting: COVID-19 and Cancer: Physician-in-Chief Lisa DeAngelis Featured on Forum About Getting Patients Back to the Clinic

(MSK/In the News) July 17, 2020 - Physician-in-Chief Lisa M. DeAngelis joins healthcare experts during the AACR Virtual Meeting: COVID-19 and Cancer to discuss how to safely bring patients to the clinic so they can receive vital cancer screenings and care.

read article

FDA Gives Project Renewal Update at AACR

(Regulatory Focus) June 24, 2020 - Generic cytotoxic cancer drugs are a cornerstone of cancer therapy, but their labels may not reflect current best evidence regarding safety and effectiveness. Progress on a pilot FDA effort to modernize labels for these drug was shared by Patricia Keegan, MD, acting associate director for medical policy at the FDA’s Oncology Center of Excellence, at the virtual annual meeting of the American Association for Cancer Research.

read article

AACR: Minority Accrual In Clinical Trials Is A Team Sport

(Regulatory Focus) June 23, 2020 - Those who conduct clinical trials are missing a broad swath of the US population, with implications that not only reach into issues of equity and justice, but may also limit the generalizability of study findings, said a cancer researcher speaking at the American Association for Cancer Research annual meeting.

read article

Diagnosing Brain Tumours With A Blood Test

(University Health Network [Canada]) June 22, 2020 - A simple but highly sensitive blood test has been found to accurately diagnose and classify different types of brain tumours, resulting in more accurate diagnosis, less invasive methods and better treatment planning in the future for the patients. The findings, published in Nature Medicine on June 22, describe a non-invasive and easy way to classify brain tumours.

read article

NCI Trials Enroll More Black Cancer Patients

(SWOG) June 22, 2020 - Black patients are better represented in taxpayer-funded clinical trials testing new cancer treatments compared to trials run by pharmaceutical companies – although black patients are not fully represented in cancer clinical trials, regardless of sponsor. These are results of a study conducted by SWOG Cancer Research Network, a member of the National Cancer Institute’s (NCI) National Clinical Trials Network (NCTN), the oldest and largest publicly-funded cancer trial network in the United States.

read press release

Personalized Cancer Vaccine Plus Atezolizumab Shows Clinical Activity in Patients With Advanced Solid Tumors

(AACR) June 23, 2020 - Treatment with the personalized cancer vaccine RO7198457 in combination with the PD-L1 inhibitor atezolizumab (Tecentriq) was well tolerated and showed clinical benefit in patients with advanced solid malignancies, according to results from a phase Ib clinical trial presented at AACR Virtual II. “Many cancers are able to successfully avoid the immune system, and we are only starting to understand the myriad ways in which cancers can do this,” said Juanita Lopez, MB BChir, PhD, a consultant medical oncologist at The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London.

read press release

Survival May Be Lower for Hispanic Patients with Blood Cancers Who Live Near the United States/Mexico Border

(AACR) June 23, 2020 - In Texas, Hispanic patients with certain blood cancers had lower overall survival than non-Hispanic white patients, and Hispanic patients living at the United States/Mexico border had lower overall survival than those who lived in other parts of Texas, according to a study presented at AACR Virtual II.

read press release

Real-world Data Shows Immunotherapy After Melanoma Surgery Yields Survival Benefit

(AACR) June 23, 2020 - Data derived from a large real-world database showed that some U.S. patients with stage 3 melanoma receive adjuvant immunotherapy (immunotherapy after surgery), and those receiving adjuvant immunotherapy had improved survival compared with those who did not, according to a study presented at AACR Virtual II.

read press release

Use of Lipophilic Statins is Associated with Lower Mortality from Ovarian Cancer

(AACR) June 23, 2020 - Lipophilic statins, a type of medication commonly prescribed to lower blood cholesterol, were associated with reduced mortality in patients with ovarian cancer, according to a study presented at AACR Virtual II.

read press release

AACR 2020 – Biontech and Roche Try to Resuscitate Cancer Vaccines

(Evaluate Vantage) June 22, 2020 - A first-in-human study of the companies’ neoantigen mRNA cancer vaccine fails to rewrite these agents’ poor history. It is surely a measure of cancer vaccines’ abysmal track record that a mere 7% overall response rate is enough for a spotlight at an oncology conference. Step forward RO7198457, a personalised neoantigen vaccine in development by Roche and Biontech, the first human data on which have just been unveiled at this year’s second virtual AACR meeting.

read article

AACR Virtual Annual Meeting 2020: Personalised Cancer Vaccine Shows Promise In Early Trial

(ICR [UK]) June 22, 2020 - A personalised cancer vaccine, used in combination with an immunotherapy drug, triggers a response from the immune system that is specific to the cancer, according to the results of an early clinical trial. Researchers found the treatment showed some clinical benefit in patients with a range of advanced cancer types and they believe it could be even more beneficial for people with earlier-stage disease who have undergone less treatment.

read article

AACR Virtual Annual Meeting 2020 II: MSK Research Shows that Young Adults with Early-Onset Cancer Are at High Risk of Harboring Inherited Genetic Mutations

(MSK) June 22, 2020 - A study from Memorial Sloan Kettering found that young patients ages 18 to 39 with early-onset cancer have an especially high risk of harboring inherited genetic (germline) mutations.

read press release

DelMar Pharmaceuticals Presents Positive Interim Data on VAL-083 Demonstrating Favorable Outcomes in Both Newly- Diagnosed and Recurrent GBM at the AACR Virtual Annual Meeting II

(DelMar) June 22, 2020 - DelMar Pharmaceuticals, Inc. today announced positive interim data from its two Phase 2 trials of VAL-083 for the treatment of glioblastoma multiforme (GBM) demonstrating improved outcomes over current standard of care as both a first-line treatment and for recurrent GBM.

read corporate press release

BriaCell Announces Presentation of Clinical and Scientific Findings at AACR Annual Meeting

(Morningstar) June 22, 2020 - Preliminary safety and efficacy data is being presented today from the clinical trials of Bria-IMT™ alone or in combination with immune checkpoint (PD-1) inhibitors in advanced breast cancer patients.

read article

BeiGene and SpringWorks Announce Presentation of Preclinical Data Combining RAF Dimer Inhibitor Lifirafenib with MEK Inhibitor Mirdametinib and Provide Update on Ongoing Phase 1b/2 Clinical Trial

(BeiGene) June 22, 2020 - Ongoing Phase 1b/2 clinical trial on track to commence dose expansion cohorts in KRAS mutant solid tumors by the end of 2020.

read corporate press release

Affimed Announces Presentation of Data on Genentech’s RO7297089 and AFM24, Both Innate Cell Engagers Developed from Affimed’s ROCK® Platform, at AACR Virtual Annual Meeting II

(Morningstar) June 22, 2020 - Data presented at AACR Virtual Annual Meeting II demonstrate that Affimed’s ROCK® platform has the ability to produce diverse Innate Cell Engagers for a multitude of hematologic and solid tumor cancers with consistent profiles in tumor lyses and safety.

read article
Next Page